Compare Carlyle Group Inc (CG) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Nuvalent Inc — how do they compare? Carlyle Group Inc trades at $47.31 (market cap $16.37B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Carlyle Group Inc is the larger of the two by market cap, and Carlyle Group Inc pays a 3.08% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| CG | NUVL | |
|---|---|---|
Market Cap | $16.37B | $9.81B |
Sector | Financials | Technology |
52-Week High | $69.35 | $123.96 |
52-Week Low | $40.52 | $72.16 |
Dividend Yield | 3.08% | — |
Enterprise Value | — | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nuvalent (NUVL) trades at $123.94, showing minimal daily movement with a 0.03% gain. The stock is in focus following GSK's proposed acquisition at $124 per share, announced June 2026. Technically, the price is at the acquisition offer level with a bullish moving average signal but overbought RSI readings. Fundamentally, the company reports significant losses with negative ROE and ROA, while cash flow remains supported by financing activities.
The investment outlook is dominated by the pending acquisition, limiting upside beyond the offer price. Key risks include deal completion uncertainty and ongoing operational losses. Analyst sentiment is mixed with a slight hold bias, reflecting caution until transaction closure. Shareholder value hinges on successful deal execution amid financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
